Loss of SPRY2 contributes to cancer-associated fibroblasts activation and promotes breast cancer development.

Huijuan Dai, Wenting Xu, Lulu Wang, Xiao Li, Xiaonan Sheng, Lei Zhu, Ye Li, Xinrui Dong, Weihang Zhou, Chenyu Han, Yan Mao, Linli Yao
{"title":"Loss of SPRY2 contributes to cancer-associated fibroblasts activation and promotes breast cancer development.","authors":"Huijuan Dai,&nbsp;Wenting Xu,&nbsp;Lulu Wang,&nbsp;Xiao Li,&nbsp;Xiaonan Sheng,&nbsp;Lei Zhu,&nbsp;Ye Li,&nbsp;Xinrui Dong,&nbsp;Weihang Zhou,&nbsp;Chenyu Han,&nbsp;Yan Mao,&nbsp;Linli Yao","doi":"10.1186/s13058-023-01683-8","DOIUrl":null,"url":null,"abstract":"<p><p>The communication between tumor cells and tumor microenvironment plays a critical role in cancer development. Cancer-associated fibroblasts (CAFs) are the major components of the tumor microenvironment and take part in breast cancer formation and progression. Here, by comparing the gene expression patterns in CAFs and normal fibroblasts, we found SPRY2 expression was significantly decreased in CAFs and decreased SPRY2 expression was correlated with worse prognosis in breast cancer patients. SPRY2 knockdown in fibroblasts promoted tumor growth and distant metastasis of breast cancer in mice. Loss of stromal SPRY2 expression promoted CAF activation dependent on glycolytic metabolism. Mechanically, SPRY2 suppressed Y10 phosphorylation of LDHA and LDHA activity by interfering with the interaction between LDHA and SRC. Functionally, SPRY2 knockdown in fibroblasts enhanced the stemness of tumor cell dependent on glycolysis in fibroblasts. Collectively, this work identified SPRY2 as a negative regulator of CAF activation, and SPRY2 in CAFs may potentially be therapeutically targeted in breast cancer treatment.</p>","PeriodicalId":9283,"journal":{"name":"Breast Cancer Research : BCR","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375677/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research : BCR","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13058-023-01683-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The communication between tumor cells and tumor microenvironment plays a critical role in cancer development. Cancer-associated fibroblasts (CAFs) are the major components of the tumor microenvironment and take part in breast cancer formation and progression. Here, by comparing the gene expression patterns in CAFs and normal fibroblasts, we found SPRY2 expression was significantly decreased in CAFs and decreased SPRY2 expression was correlated with worse prognosis in breast cancer patients. SPRY2 knockdown in fibroblasts promoted tumor growth and distant metastasis of breast cancer in mice. Loss of stromal SPRY2 expression promoted CAF activation dependent on glycolytic metabolism. Mechanically, SPRY2 suppressed Y10 phosphorylation of LDHA and LDHA activity by interfering with the interaction between LDHA and SRC. Functionally, SPRY2 knockdown in fibroblasts enhanced the stemness of tumor cell dependent on glycolysis in fibroblasts. Collectively, this work identified SPRY2 as a negative regulator of CAF activation, and SPRY2 in CAFs may potentially be therapeutically targeted in breast cancer treatment.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
SPRY2的缺失有助于癌症相关成纤维细胞的激活并促进乳腺癌的发展。
肿瘤细胞与肿瘤微环境之间的交流在肿瘤的发生发展中起着至关重要的作用。癌症相关成纤维细胞(cancer -associated fibroblasts, CAFs)是肿瘤微环境的主要组成部分,参与乳腺癌的形成和发展。本文通过比较CAFs和正常成纤维细胞的基因表达模式,我们发现SPRY2在CAFs中表达明显降低,并且SPRY2表达降低与乳腺癌患者预后较差相关。SPRY2在成纤维细胞中的下调促进了小鼠乳腺癌的肿瘤生长和远处转移。基质SPRY2表达的缺失促进了依赖糖酵解代谢的CAF激活。机械上,SPRY2通过干扰LDHA和SRC之间的相互作用来抑制LDHA的Y10磷酸化和LDHA活性。功能上,SPRY2在成纤维细胞中的下调增强了肿瘤细胞依赖于成纤维细胞糖酵解的干性。总的来说,这项工作确定了SPRY2是CAF激活的负调节因子,CAF中的SPRY2可能是乳腺癌治疗的潜在治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
siRNA treatment targeting integrin α11 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progression. Quantitative characterization of breast lesions and normal fibroglandular tissue using compartmentalized diffusion-weighted model: comparison of intravoxel incoherent motion and restriction spectrum imaging AMD1 promotes breast cancer aggressiveness via a spermidine-eIF5A hypusination-TCF4 axis NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer Receptor conversion and survival in breast cancer liver metastases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1